LONDON - Oxford BioMedica plc is acquiring its fellow immunotherapy specialist Oxxon Therapeutics Ltd. in an all-paper deal that values Oxxon at £12 million (US$23.3 million). In addition to six clinical stage products, the deal brings Oxford BioMedica £3 million in cash. (BioWorld International) Read More
